免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Intermittent Tacrolimus Treatment Delays CD8+ Tumor-Infiltrating Lymphocyte Exhaustion and Enhances PD1 Blockade Therapy in Melanoma-Bearing Mice.
Intermittent Tacrolimus Treatment Delays CD8+ Tumor-Infiltrating Lymphocyte Exhaustion and Enhances PD1 Blockade Therapy in Melanoma-Bearing Mice.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
持续抗原暴露启动CD8+ T细胞耗竭的发育过程,伴随抑制性受体(IRs)表达的逐渐增加。我们先前的研究将T细胞耗竭概念化为慢性抗原刺激诱导的过度激活状态。为干预CD8+ T细胞耗竭的发育过程,我们通过他克莫司(一种T细胞活化抑制剂)间歇性阻断T细胞活化信号,从而调整过度激活状态。荷黑色素瘤小鼠接受间歇性他克莫司(IT)和/或程序性细胞死亡1(PD1)阻断抗体治疗。通过流式细胞术检测CD8+TIL(肿瘤浸润淋巴细胞)(CD8+TILs)的耗竭表型。利用IRs(PD1和CD223)以及记忆标志物(Ly108和CD127)的表达水平来界定CD8+TILs耗竭的程度。随后,使用酪氨酸酶相关蛋白2肽(Trp2 180-188)检测肿瘤特异性CD8+TILs。
此外,还评估了肿瘤生长速率和肿瘤重量。我们发现IT和/或PD1阻断增强了功能性CD8+TILs的浸润。研究结果表明,IT治疗和PD1阻断均增强了抗肿瘤免疫。联合IT和PD1阻断导致肿瘤生长速率和肿瘤重量的更大程度降低。IT治疗还改善了CD8+TILs对黑色素瘤特异性Trp2 180-188肽的应答。对CD8+TILs的详细分析显示,随着PD1表达增加,Ly108和CD127显著降低。与PD1阻断相比,联合治疗(IT加PD1阻断)显著增加了表达中等水平IRs的CD8+TILs数量,同时减少了表达高水平IRs的CD8+TILs数量。这些结果表明,联合治疗增强了CD8+TILs的功能并减缓了IRs表达的增加,延缓了CD8+TILs耗竭的发育过程。
Continuous antigen exposure initiates the developmental process of CD8+ T cell exhaustion, accompanied by a gradual increase in the expression of inhibitory receptors (IRs).
Our previous study conceptualized T cell exhaustion as an over-activation status induced by chronic antigen stimuli. To intervene in the developmental process of CD8+ T cell exhaustion, we adjusted the over-activation status by intermittently blocking T cell activation signals with tacrolimus, a T cell activation inhibitor. Melanoma-bearing mice received intermittent tacrolimus (IT) and/or programmed cell death 1 (PD1) blockade antibody.
Exhaustion phenotype of CD8+ tumor-infiltrating lymphocytes (CD8+TILs) was detected by flow cytometry. The expression levels of IRs (PD1 and CD223), as well as memory markers (Ly108 and CD127), were utilized to demarcate the extent of CD8+TILs exhaustion. Then, tyrosinase-related protein 2 peptide (Trp2 180-188 ) was used to detect tumor-specific CD8+ TILs.
Furthermore, tumor growth rate and tumor weight were also evaluated.
We found that IT and/or PD1 blockade enhanced the infiltration of functional CD8+TILs. The findings demonstrated that both IT therapy and PD1 blockade enhanced the antitumor immunity. Combining IT and PD1 blockade led to a greater reduction in tumor growth rate and tumor weight. IT therapy also improved the response of CD8+TILs to melanoma-specific Trp2 180-188 peptide. A detailed analysis of the CD8+TILs showed that Ly108 and CD127 reduced dramatically as the expression of PD1 increased.
In comparison to PD1 blockade, combined treatment (IT plus PD1 blockade) significantly increased the number of intermediate IRs-expressing CD8+TILs, while reducing the number of high IRs-expressing CD8+TILs. These results indicated that combined treatment enhanced the function and decelerated the increase in IRs expression of CD8+TILs, deferring the developmental process of CD8+TILs exhaustion.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。